Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CDK8 | P49336 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 7/20 | 0.73 |
| ▸ | ABL1 | P00519 | 7/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.62 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | BCR | P11274 | 2/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.60 |
| ▸ | STK25 | O00506 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.60 |
| ▸ | IKBKB | O14920 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676641 | 1.00 | CDK2 (1.00) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL3681671 | 0.93 | CDK2 (0.88) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL29678397 | 0.93 | CDK2 (0.88) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL4937809 | 0.92 | CDK2 (0.85) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL4931472 | 0.91 | CDK2 (0.84) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL4936685 | 0.90 | CDK8 (0.82) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL13991160 | 0.90 | CDK2 (0.82) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL29827937 | 0.86 | CDK2 (0.75) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL4769220 | 0.86 | CDK2 (0.75) | CDK2CDK8CDK1SRCABL1 | |
| SCHEMBL21910051 | 0.86 | CDK2 (0.75) | CDK2CDK8CDK1SRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | SONIC MASTER LIMITED (VG) | 2022-07-05 | — | — | US | disclosed |
| WO-2022129627-A1 | OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS | PHI PHARMA SA (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015004-A1 | PROTEOGLYCAN SPECIFIC BRANCHED PEPTIDES | Phi Pharma SA (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CCR10, SLC11A2, MSR1 | CDK2 2492/4885CDK8 2790/4885CDK1 2956/4885 |
| US-11452716-B2 | Pharmaceutical composition and use thereof | TP53, RB1, CDK20 | CDK2 4/4885CDK8 18/4885CDK1 12/4885 |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | MYLK2, MUSK, CKMT1A; CKMT1B | CDK2 16/4885CDK8 77/4885CDK1 20/4885 |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | CHI3L1, CHI3L2, ACE2 | CDK2 4490/4885CDK8 4825/4885CDK1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.